Divalproex Sodium
Product Images NDC 64725-0798

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 64725-0798). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Tya Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (64725 0797)

A label for Divalproex Sodium DR 250 mg tablets, showing a package of 15 tablets. The label indicates prescription use only and lists Sun Pharma as the manufacturer. It was repackaged by TYA Pharmaceuticals in Tallahassee, Florida. The label includes a barcode and contact phone number, with placeholders for lot number and expiration date. Dosage instructions advise consulting the package insert.*

FDA Label Image

Label Image (64725 0798)

Label for Divalproex Sodium delayed-release 500 mg tablets in a 100-count bottle. The manufacturer is Sun Pharma, with repackaging by T.Y.A. Pharmaceuticals in Tallahassee, Florida. The label includes lot and expiration placeholders, a barcode, and directs to see the package insert for dosing information.*

FDA Label Image

Divalproex-na-fig1 (Divalproex Na Fig1)

A bar chart comparing the percentage results between placebo (PBO) and Divalproex sodium delayed-release tablets (DVPX) in two studies, labeled Study 1 (YMRS) and Study 2 (MRS). Percentages for DVPX are 60% and 58%, while for placebo they are 26% and 29%, respectively, with statistical significance indicated (p < 0.05).*

FDA Label Image

Divalproex-na-fig2 (Divalproex Na Fig2)

A bar chart comparing two studies showing mean doses or outcomes for placebo versus Divalproex Sodium delayed-release tablets (DVPX). The chart includes numeric scales and annotations indicating dosing information for Divalproex Sodium in both studies, labeled as Study 1 and Study 2.*

FDA Label Image

Divalproex-na-fig3 (Divalproex Na Fig3)

A Kaplan-Meier curve graph depicting percent reduction in complex partial seizure (CPS) rate for patients treated with Divalproex Sodium delayed-release tablets (DVPX) versus placebo. The graph shows percentage of patients on the x-axis and percent reduction in CPS rate on the y-axis, with improvement upwards and worsening downwards.*

FDA Label Image

Divalproex-na-fig4 (Divalproex Na Fig4)

A cumulative percentage chart comparing the percent reduction in CPS rate among patients receiving high and low doses of Divalproex Sodium. The y-axis shows percent reduction in CPS rate ranging from -100% to 100%, with labels indicating improvement, no change, and worsening. The x-axis shows percent of patients from 0 to 100, with curves for high dose and low dose groups.*

FDA Label Image

Divalproex-na-structure (Divalproex Na Structure)

Chemical structure of divalproex sodium showing the sodium salt of valproic acid polymer with carboxylate and alkyl chain groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.